We take real pharmacy and Covered Entity data and model projected claim volume, pricing impact, and potential savings or revenue. Our projections eliminate guesswork and help both parties make informed decisions before signing or expanding a 340B contract.
We evaluate your program’s structure, data integrity, capture rate, and financial performance. The result is a clear view of where value is realized, where it’s being missed, and what changes can improve program performance and compliance.
Yes. We determine which path (340B pricing vs. rebate) is most advantageous for each claim and manage the submission and reconciliation process. For ESP, we prepare and submit claims to lift manufacturer restrictions and restore access to 340B pricing where possible — without risking duplicate discounts.
Absolutely. We provide continuous monitoring, reporting, and audit-ready documentation — ensuring the program remains transparent, compliant, and financially optimized for both the Covered Entity and Pharmacy.
No. We work alongside TPAs, Beacon, MFP, and ESP platforms to validate data, identify missed opportunities, and ensure that every eligible claim goes to the right path. We are the strategic oversight layer — not the data pipeline.
Pharmacies may only participate in 340B by contracting with an eligible 340B facility. Visit the 340B database to search for potential opportunities in your area.
Covered Entities looking to add or expand their Contract Pharmacy reach should inquire on our contact page for more information and to begin data discovery. We have extensive knowledge and experience in determining which pharmacies are beneficial and how to structure the arrangement.
There is flexibility for 340B Contract Pharmacy arrangements. Looking at the program as a whole, there are a variety of ways contracts can be structured and optimized to be more efficient and beneficial for both Pharmacies and Covered Entities. Data and modeling are the keys to determining where the balance lies. That is precisely why Secure340B is an important tool for objective analysis.
Inventory is a pharmacy’s largest expense and the number one factor in managing cash flow. 340B can negatively impact a pharmacy financially if inventory isn’t managed correctly. It is important to use the tools available to assist and prevent duplicate ordering or excess inventory (swell). It is also important to take an in-depth look at your program to evaluate if there are ways to lessen the inventory burden from 340B.”
340B Programs move drug purchases from a pharmacy retail wholesaler account to the Covered Entity 340B account. There is no question this has an impact on pharmacy wholesaler rebates. It is important to take an in-depth look at your program to evaluate if there are ways to reduce the impact on wholesaler rebates.